Seongnam, South Korea · Founded 2017 · Privately Held (backing)
Developer of healthcare immunotherapies designed to treat serious diseases such as cancer and autoimmune disorders. MediMabBio is based in Seongnam, South Korea and was founded in 2017. It has raised $37.9 million.
Last price · $/share
—
Implied valuation
—
Total raised
$37.9M
Last round
—
Cap table — not yet on record
MediMabBio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of MediMabBio with a free account
·The complete investor list: 19 names
·Watch MediMabBio: the Monday email on marks, rounds and moves
